drugset / Trial / NCT05431569
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
A non-randomized, open, Simon'soptimal2-stage study to evaluate the efficacy and safety of 6MW3211 in patients with advanced Lung Cancer who had failed therapy with PD-1/L1 Inhibitor.
Timeline
- Start
- 2022-07-10
- Primary completion
- 2022-12-10
- Completion
- 2023-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SAFIMESTOMIG | Monoclonal antibody | 30 mg/kg | Intravenous |